Drug intelligence / Profile preview

INV-7082

Development stage: Preclinical
Lead developer: Ionova Life Science
Modality: Small Molecules

Overview

INV-7082 is a preclinical-stage small molecule antagonist of the Prostaglandin E receptor 4 (EP4), developed by Ionova Life Sciences for the treatment of inflammatory pain. The EP4 receptor is a high-affinity G protein-coupled receptor for prostaglandin E2 (PGE2) and is heavily involved in the sensitization of nociceptors and the mediation of inflammatory responses. By selectively blocking EP4 signaling, INV-7082 aims to provide potent analgesic and anti-inflammatory effects while potentially avoiding the gastrointestinal and cardiovascular side effects associated with non-selective cyclooxygenase (COX) inhibitors. The drug is currently undergoing preclinical evaluation to support its transition into clinical trials.

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on INV-7082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-7082.

Explore the full profile